Moderna, Inc. and OpenAI today announced an ongoing collaboration to co-innovate around a shared vision of AI's transformative potential for the future of business and healthcare.
Moderna is a digital-first company that has harnessed the power of machine learning since its inception.
With this strong data foundation and its robust learning culture, the company is positioned to responsibly and seamlessly integrate generative AI into its operations and leverage next-generation AI innovations.
The two organizations began working together in early 2023 by launching Moderna's ChatGPT instance, called mChat, built internally on OpenAI's API.
Achieving over 80% internal adoption since its debut, this early success accelerated the AI culture and led to the introduction of ChatGPT Enterprise and its enhanced capabilities such as advanced analytics, image generation, and GPT.
These GPTs are now embedded across Moderna's business functions, from legal to research to manufacturing to commercial, and are purpose-built to serve as assistants to Moderna employees, empowering them through personalized support. is strengthening its role.
These tools will serve as an extension of Moderna's team, allowing the company to advance its mission to have the greatest impact possible on people through mRNA medicines.
Stéphane Bancel, CEO of Moderna, commented in a press release on April 24, 2024: Maximize patient impact. ”
